Pfizer and BioNTech have shared positive data for their vaccine candidate, which is currently in phase I/II. A week after receiving a second dose, subjects had neutralizing antibodies against SARS-CoV-2 and reported no adverse reactions. A larger, global phase 2b/3 safety and efficacy study may begin as soon as this month. Yourway is a trusted clinical supplies courier, with the logistics experience needed to keep clinical trials running globally.